Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel
Molecular Oncology · 2026
DOI: 10.1002/1878-0261.70136 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Molecular Oncology, 2026. Verfasst von Elisabeth Spenard und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, University of Toronto, Canada. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Carcinoma, Ovarian Epithelial, Germ-Line Mutation, Ovarian Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Surgical Oncology Innovations in Translational and Basic Science Research Grant from University Health Network, University of Toronto.
Abstract (Originalsprache)
Genetic testing in epithelial ovarian cancer (EOC) in Ontario includes germline next‐generation sequencing (NGS) for 19 genes. Additionally, tumor tissue undergoes reflex NGS testing for BRCA1/2 to assess eligibility for PARPi. Although parallel testing confers advantages, this model duplicates healthcare resources. Here, we prospectively assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood. An 18‐gene NGS panel was used to test tumor and germline DNA ( n = 106 patients). In 26 patients, 27 tumor Tier I or II variants were identified, with 16/27 (59%) being germline pathogenic variants (PV) (13 BRCA1/2 ; 3 other genes) and 11/27 (41%) somatic variants (9 BRCA1/2 ; 2 other). In 51/106 patients, there were no tumor variants (excluding TP53 ), of which one patient had a germline BRCA1 copy number variant deletion in exon 12. Tumor‐first testing detected variant‐positive and variant‐negative germline cases in 105/106 patients (99.1%). Among 50 BRCA ‐negative patients, 14/50 (28%) were homologous recombination deficiency (HRD)‐positive. Therefore, we demonstrate that multigene NGS tumor‐testing is effective in identifying germline variants in EOC with a < 1% false‐negative rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gynecologic Oncology, University of Toronto, Canada.
- Division of Gynecologic Oncology, Princess Margaret Cancer Centre, University Health Network, Canada.
- Institute of Health Policy, Management and Evaluation, University of Toronto, Canada.
- Division of Gynecologic Oncology, Laval University, Québec City, Canada.
- Laboratory Medicine Program, Division of Clinical Laboratory Genetics, University Health Network, Canada.
- Department of Molecular Genetics, University of Toronto, Canada.
ORCID-Profile: Cristina Mitric, Tracy L Stockley
Förderung
- Surgical Oncology Innovations in Translational and Basic Science Research Grant from University Health Network, University of Toronto
Zitieren
APA
Spenard, E., Mitric, C., Care, M., Stockley, T. L., Kim, R. H., McCuaig, J., Clarke, B., Ranich, L., Sheen, C., Ferguson, S. E., Hogen, L., May, T., & Bernardini, M. Q. (2026). Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel. Molecular Oncology. https://doi.org/10.1002/1878-0261.70136
Vancouver
Spenard E, Mitric C, Care M, Stockley TL, Kim RH, McCuaig J, et al. Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel. Molecular Oncology. 2026. doi:10.1002/1878-0261.70136
BibTeX
@article{Spenard2026,
author = {Spenard, Elisabeth and Mitric, Cristina and Care, Melanie and Stockley, Tracy L and Kim, Raymond H and McCuaig, Jeanna and Clarke, Blaise and Ranich, Laura and Sheen, Clare and Ferguson, Sarah E and Hogen, Liat and May, Taymaa and Bernardini, Marcus Q},
title = {Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel},
journal = {Molecular Oncology},
year = {2026},
doi = {10.1002/1878-0261.70136}
}
EUVIMED